LILLE, France--(BUSINESS WIRE)--ALZPROTECT (http://www.alzprotect.com/en), a biopharmaceutical company developing treatments for Alzheimer’s disease, today ...
Rep. Jennifer Wexton (D-VA) announced that she will not seek reelection in 2024 after having been diagnosed with the rare degenerative disorder progressive supranuclear palsy. The 55-year-old ...
GemVax & Kael Kael announced on the 28th that it has completed patient recruitment for the domestic Phase 2 clinical trial of GV1001, a treatment for progressive supranuclear palsy (PSP). The Phase 2 ...
This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) in slowing the progression ...
A clinical trial that will test three drugs concurrently, and could include more, represents new hope for patients with progressive supranuclear palsy (PSP), an incurable neurodegenerative disorder ...
A clinical trial that will test three drugs concurrently, and could include more, represents new hope for patients with progressive supranuclear palsy (PSP), an incurable neurodegenerative disorder ...
GemVax Applies for IND for GV1001 Phase 2 Clinical Trial in Progressive Supranuclear Palsy Treatment
[Asia Economy Reporter Jang Hyowon] GemVax & Kael announced on the 29th that it has applied to the Ministry of Food and Drug Safety for approval of the domestic Phase 2a clinical trial plan (IND) for ...
Spanish international pharmaceutical company Ferrer has announced the completion of patient recruitment for the PROSPER study, a Phase II clinical trial designed to assess the efficacy, safety, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback